TMB-365/TMB-380 Combination Demonstrates Viral Suspension Without the Need for Susceptibility Screening
TaiMed Biologics will reshape HIV treatment management and seeks strategic collaborations with global pharmaceutical partners for the commercialization of its long-acting HIV maintenance therapy
TAIPEI, March 18, 2025 /PRNewswire/ -- TaiMed Biologics (4147 TWO), an innovation-driven biotech company, has Phase 2a clinical study evaluating TMB-365/TMB-380 long-acting dual bNAb regimen for HIV maintenance therapy. This regimen, which is the first of its kind, offers a viable alternative to daily oral cART for individuals living with HIV.
Key findings from the trial include durable viral suppression, with 94% of participants maintaining RNA levels below 50 copies/mL throughout the treatment period, while only the remaining 6% of participants recorded viral load of 59 copies/mL at end of 24-week treatment. No pre-defined virologic failure, which were defined as two consecutive viral load measurements above 50 copies/mL.
The treatment was well-tolerated, with no serious adverse events, no Grade 3 or Grade 4, or acute infusion reactions reported. Additionally, no participants experienced treatment-limiting immune responses to the combination therapy.
One of the more remarkable findings of TMB-365/TMB-380 is that it does not require susceptibility screening as the combination's broad breadth of activity and high potency, participants were not pre-screened for susceptibility to either bNAb featured for lowering the barrier to treatment access and ensures a wider range of individuals living with HIV can benefit from the therapy.
Additionally, the pharmacokinetic (PK) and immunological markers also support the potential for long-acting viral suppression and stable immune function. This Phase 2a clinical trial was not a double-blind placebo-controlled study, and therefore, no statistical p-values were reported.
"We are honored that our study was accepted for late-breaking presentation at CROI, highlighting the high scientific merit and groundbreaking nature of our results among numerous research studies, TMB-365/TMB-380 is the first long-acting mAb combination to achieve a high rate of viral suppression without screening requirements with robust potency, broad coverage and low resistance risk The regimen aims to reduce the frequency of daily dosing, while maintaining treatment's efficacy," said Dr. Jimmy Chang, CEO of TaiMed Biologics.
"The global HIV treatment market valued at approximately USD 30 billion annually, with long-acting treatments currently account for only 3% but are projected to increase to over 30-40% in the coming years. The outstanding Phase 2a results position TMB-365/TMB-380 as a frontrunner in this rapidly growing sector, offering clear advantages over existing long-acting treatment options," emphasized by Dr. Jimmy Chang.
TaiMed Biologics is actively seeking strategic collaborations with global pharmaceutical partners to support the commercialization of TMB-365/TMB-380. TaiMed Biologics welcomes opportunities to explore potential collaborations with global pharmaceutical partners to advance the commercialization of TMB-365/TMB-380
For more information, please contact: Jonathan Ho, jho@taimedbio.com.
About TaiMed Biologics
Founded in 2007, TaiMed Biologics (4147.TWO) is a leading commercial-stage biotechnology company focused on developing innovative therapies for HIV treatment. The company successfully launched ibalizumab (Trogarzo®), the world's first and only FDA-approved monoclonal antibody for HIV and continues to pioneer long-acting biologics and antibody-drug conjugates (ADCs). TaiMed Biologics also offers comprehensive contract development and manufacturing (CDMO) services and is publicly traded on the OTC Market since November 2015, currently part of the MSCI Small Cap Index.
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
TaiMed Biologics Announces Results from Late-Breaking Phase 2a Data on Long-Acting HIV Maintenance Therapy at CROI 2025
In the news release, Workato to Launch "The Work Revolution" National Developer Challenge, issued 17-Mar-2025 by Workato over PR Newswire, we are advised by the company that in the last line of the last paragraph, the submission deadline for the developer challenge should be "21 April 2025" rather than "18 April 2025" as originally issued inadvertently. The complete, corrected release follows:
Workato to Launch "The Work Revolution" National Developer Challenge
The Work Revolution, a nationwide developer challenge, supports the development of cutting-edge integration, automation and AI solutions for a transformed workplace.
SINGAPORE, March 18, 2025 /PRNewswire/ -- Workato, the leading Enterprise Orchestration platform, supported by Singapore's Infocomm Media Development Authority (IMDA), has launched "The Work Revolution" Developer Challenge, a nationwide developer challenge aimed at fostering innovation for the future of work. This initiative invites developers to create cutting-edge integration, automation and artificial intelligence (AI) solutions that transform workplace productivity.
Empowering innovators to shape the future of work
With 85 percent of business leaders anticipating a surge in skills development needs due to AI and digital trends in the next three years, this challenge presents developers with a unique opportunity to get ahead of this curve for the future economy. This challenge, open to students, developers, IT professionals, and citizen developers, will feature a prize pool of over S$18,000 in cash. Finalists will be pitching their innovative ideas to a distinguished panel of judges made up of public and private sector leaders.
The Work Revolution Developer Challenge focuses on five critical domains relevant to modern enterprise solutions: security, employee experience, customer experience, operational excellence, and social sector impact. Participants of this challenge will have full access and hands-on experience with Workato's enterprise automation platform and its cutting-edge AI capabilities. Through this initiative, developers can also gain practical experience to build a robust AI foundation that enhances future career development. By championing innovative solutions across these areas, Workato and IMDA aim to unlock new possibilities for workplace transformation and technological advancement.
"As a strategic partner of IMDA, Workato will continue to empower the broader community to contribute to the transformation of Singapore's digital economy. This new partnership looks outwards, tapping into the creativity and ingenuity of the wider community to drive the next wave of workplace innovation. This competition is a fantastic opportunity for aspiring innovators to put their ideas into motion and develop skills that will make a real impact on the future of work," said Vijay Tella, co-founder and CEO of Workato.
The first-place winner will be awarded S$10,000 cash prize and the opportunity to speak at Workato's flagship conference. The second and third place winners will win S$5,000 and S$3,000 respectively. In addition, all finalists will receive Workato-led exclusive training and mentorship as they prepare for the final presentation.
Driving digital transformation through collaboration
This initiative aims to advance Singapore's Smart Nation vision by enabling local talent to tackle real-world business challenges. By providing enterprise-grade tools and the opportunity for hands-on innovation, it exemplifies Workato and IMDA's commitment to jointly foster inclusive growth and digital transformation across Singapore's workforce, reinforcing Singapore's position as a trusted digital innovation hub.
"We look forward to seeing the winning solutions that will come out of this Developer Challenge, which is focused on driving innovation for the future of work. We believe Workato's enterprise automation platform will empower budding developers to create forward-thinking integration, automation, and AI solutions that will transform workplace productivity", said Edwin Low, Director of Enterprise & Ecosystem Development at the IMDA.
Named a Leader in the 2024 Gartner® Magic Quadrantâ„¢ for iPaaS, Workato enables enterprises to transform their business operations by orchestrating business processes end-to-end and operationalizing AI across the entire organization. Workato has helped leading enterprises in Asia Pacific, including Fullerton Health, Gulf Marine, and Jollibee Food Corporation, accelerate digitalisation across their business.
Interested parties can register for the challenge and pre-event trainings happening once a month through the official website. The entry submission deadline is 21 April 2025, at 11:59 PM SGT.
+++
About Workato
Workato transforms technology complexity into business opportunity. As the leader in enterprise orchestration, Workato helps businesses globally streamline operations by connecting data, processes, applications, and experiences. Its AI-powered platform enables teams to navigate complex workflows in real-time, driving efficiency and agility. Trusted by over 12,000 global customers. Workato empowers organizations of every size to unlock new value and lead in today's fast-changing world. Learn how Workato helps businesses of all sizes achieve more at workato.com.
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
Workato to Launch "The Work Revolution" National Developer Challenge
Workato to Launch "The Work Revolution" National Developer Challenge
